Compare IMXI & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMXI | RGNX |
|---|---|---|
| Founded | 1994 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 528.6M |
| IPO Year | 2016 | 2015 |
| Metric | IMXI | RGNX |
|---|---|---|
| Price | $14.51 | $13.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $15.00 | ★ $28.75 |
| AVG Volume (30 Days) | 451.5K | ★ 2.4M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.08 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $319,601,000.00 | $10,393,000.00 |
| Revenue This Year | $0.83 | $51.21 |
| Revenue Next Year | $1.49 | $19.08 |
| P/E Ratio | $727.00 | ★ N/A |
| Revenue Growth | 16.68 | ★ 126.48 |
| 52 Week Low | $8.58 | $5.46 |
| 52 Week High | $15.95 | $16.19 |
| Indicator | IMXI | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 83.90 |
| Support Level | $13.91 | $12.87 |
| Resistance Level | $15.32 | $13.86 |
| Average True Range (ATR) | 0.41 | 1.02 |
| MACD | 0.06 | 0.63 |
| Stochastic Oscillator | 69.83 | 90.67 |
International Money Express Inc is an omnichannel money remittance services company focused on the United States of America to Latin America and the Caribbean corridor, which includes Mexico, Central and South America and the Caribbean. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.